Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy.

Flashner-Abramson E, Vasudevan S, Adejumobi IA, Sonnenblick A, Kravchenko-Balasha N.

Theranostics. 2019 Jul 9;9(18):5149-5165. doi: 10.7150/thno.31657. eCollection 2019.


Personalized disease signatures through information-theoretic compaction of big cancer data.

Vasudevan S, Flashner-Abramson E, Remacle F, Levine RD, Kravchenko-Balasha N.

Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7694-7699. doi: 10.1073/pnas.1804214115. Epub 2018 Jul 5.


Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks.

Su SP, Flashner-Abramson E, Klein S, Gal M, Lee RS, Wu J, Levitzki A, Daly RJ.

Mol Cancer Ther. 2018 May;17(5):931-942. doi: 10.1158/1535-7163.MCT-17-0377. Epub 2018 Feb 12.


PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.

Langut Y, Talhami A, Mamidi S, Shir A, Zigler M, Joubran S, Sagalov A, Flashner-Abramson E, Edinger N, Klein S, Levitzki A.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13655-13660. doi: 10.1073/pnas.1714587115. Epub 2017 Dec 11.


PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.

Langut Y, Edinger N, Flashner-Abramson E, Melamed-Book N, Lebendiker M, Levi-Kalisman Y, Klein S, Levitzki A.

Oncotarget. 2017 Apr 11;8(15):24046-24062. doi: 10.18632/oncotarget.15733.


Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.

Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, Karin M.

Oncogene. 2016 May 19;35(20):2634-44. doi: 10.1038/onc.2015.326. Epub 2015 Sep 14.


Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.

Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y, Bar-Eli M, Reuveni H, Levitzki A.

Oncogene. 2016 May 19;35(20):2675-80. doi: 10.1038/onc.2015.229. Epub 2015 Jun 29.


Therapeutic destruction of insulin receptor substrates for cancer treatment.

Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A.

Cancer Res. 2013 Jul 15;73(14):4383-94. doi: 10.1158/0008-5472.CAN-12-3385. Epub 2013 May 7.

Supplemental Content

Loading ...
Support Center